Update - Proposed issue of securities - AT1
Released
Released
Announcement PDF
Proposed issue of securities
Update Summary
Entity name
ATOMO DIAGNOSTICS LIMITED
Announcement Type
Update to previous announcement
Date of this announcement
28/7/2023
Reason for update to a previous announcement
To advise proposed director participation in the SPP announced on 13 July 2023
Refer to next page for full details of the announcement
Proposed issue of securities
1/7
Proposed issue of securities
Part 1 - Entity and announcement details
1.1 Name of +Entity
ATOMO DIAGNOSTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees
to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in
Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also
apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set
out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under
the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX
an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type
Registration Number
ABN
37142925684
1.3 ASX issuer code
AT1
1.4 The announcement is
Update/amendment to previous announcement
1.4a Reason for update to a previous announcement
To advise proposed director participation in the SPP announced on 13 July 2023
1.4b Date of previous announcement to this update
13/7/2023
1.5 Date of this announcement
28/7/2023
1.6 The Proposed issue is:
An offer of +securities under a +securities purchase plan
Proposed issue of securities
2/7
Proposed issue of securities
Part 4 - Details of proposed offer under securities purchase plan
Part 4A - Conditions
4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities
under the +securities purchase plan issue can proceed on an unconditional basis?
Yes
4A.1a Conditions
Approval/Condition
Date for determination
+Security holder approval
15/9/2023
Is the date estimated or
actual?
** Approval
received/condition met?
Estimated
Comments
AT1 has applied to ASX for a LR 7.1 waiver to permit the issue of SPP Shares without shareholder approval. It is
proposed that AT1's Chair John Keith will apply for AUD15,000 worth of SPP Shares based on a SPP price of 3.6c. AT1
has also applied for a LR 10.11 waiver to permit the participation of directors and their associates in the SPP. In the event
that the waivers are not granted, shareholder approval will be sought at an EGM.
Proposed issue of securities
3/7
Proposed issue of securities
Part 4B - Offer details
Class or classes of +securities that will participate in the proposed issue and class or classes of +securities
proposed to be issued
ASX +security code and description
AT1 : ORDINARY FULLY PAID
Will the proposed issue of this
+security include an offer of
attaching +securities?
No
Details of +securities proposed to be issued
ASX +security code and description
AT1 : ORDINARY FULLY PAID
Maximum total number of those +securities that could be issued
if all offers under the +securities purchase plan are accepted
76,388,888
Will the offer be conditional on applications for a minimum
number of +securities being received or a minimum amount
being raised (i.e. a minimum subscription condition)?
No
Will the offer be conditional on applications for a maximum
number of +securities being received or a maximum amount
being raised (i.e. a maximum subscription condition)?
No
Will individual security holders be required to accept the offer for
a minimum number or value of +securities (i.e. a minimum
acceptance condition)?
Yes
Is the minimum acceptance unit based or dollar based?
Dollar based ($)
Please enter the minimum acceptance value
$ 1,000
Will individual security holders be limited to accepting the offer
for a maximum number or value of +securities (i.e. a maximum
acceptance condition)?
Yes
Is the maximum acceptance unit based or dollar based?
Dollar based ($)
Please enter the maximum acceptance value
$ 30,000
Proposed issue of securities
4/7
Proposed issue of securities
Describe all the applicable parcels available for this offer in number of securities or dollar value
$1,000, $2,500, $7,500, $10,000, $15,000, $20,000, $30,000
Offer price details
Has the offer price been determined?
Yes
In what currency will the offer
be made?
What is the offer price per
+security?
AUD - Australian Dollar
AUD 0.03600
Oversubscription & Scale back details
Will a scale back be applied if the offer is over-subscribed?
Yes
Describe the scale back arrangements
Applications may be scaled back at the absolute discretion of the Company.
Will these +securities rank equally in all respects from their issue date with the existing issued
+securities in that class?
Yes
Part 4C - Timetable
4C.1 Date of announcement of +security purchase plan
13/7/2023
4C.2 +Record date
12/7/2023
4C.3 Date on which offer documents will be made available to investors
18/7/2023
4C.4 Offer open date
18/7/2023
4C.5 Offer closing date
1/8/2023
4C.7 +Issue date and last day for entity to announce results of +security
purchase plan offer
8/8/2023
Proposed issue of securities
5/7
Proposed issue of securities
Part 4D - Listing Rule requirements
4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5
or do you have a waiver from those requirements?
No
4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity's 15%
placement capacity under listing rule 7.1?
Yes
4D.1a ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's
15% placement capacity under listing rule 7.1?
All of the new shares proposed to be issued under the SPP, including allotments to directors and their associates, subject
to ASX granting a waiver of LR 7.1 and LR 10.11
4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's
additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
Part 4E - Fees and expenses
4E.1 Will there be a lead manager or broker to the proposed offer?
Yes
4E.1a Who is the lead manager/broker?
Bell Potter
4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?
The lead manager's fees comprise 6% of the funds raised under the SPP offer, with the exception of funds received from
GZ Family Office.
4E.2 Is the proposed offer to be underwritten?
No
4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a
handling fee or commission?
No
4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer
Proposed issue of securities
6/7
Proposed issue of securities
Part 4F - Further Information
4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
To fund hCG Pregnancy Test sales & marketing (ANZ/US); Iron Deficiency Test registration & commercial activity
(ANZ/UK and Europe); POC Technology (OEM) business development; Product development (app, digital, Vitamin D);
and working capital requirements.
4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
No
4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer
Shareholders who are not resident in Australia or New Zealand or the United Kingdom will not be able to participate in the
SPP.
4F.3 URL on the entity's website where investors can download information about the proposed offer
https://investors.atomodiagnostics.com/investor-centre/?page=asx-announcements
4F.4 Any other information the entity wishes to provide about the proposed offer
Proposed issue of securities
7/7
Share your feedback
Discover